Journal profile · Oncology
Cancer Biology & Therapy
ISSN 1538-4047 · eISSN 1555-8576 · Landes Bioscience · UNITED STATES · Monthly · Founded 2002
Cancer Biology & Therapy: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 5.7; JCR Q1 (journal website); fully open access; APC about USD 3,300; median 134 days to acceptance (94 articles, last 24 months); community-reported acceptance: about 50%; 88 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Biology & Therapy is published by Landes Bioscience and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer-related Molecular Pathways, Cancer, Hypoxia, and Metabolism and Cell death mechanisms and regulation, together about 20% of its articles. Its main subfields are Cancer Research and Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Please note, from 2022 the Print ISSN is not in active use as this journal is no longer published in print. Cancer Biology & Therapy is a high-profile international journal examining all aspects of the molecular basis of cancer, with translational relevance to diagnosis and therapy. The goal is to foster communication and the rapid exchange of information through timely publication of important advances within the field. Topics covered include: Existing and emerging technologies such as genome sequencing to increase understanding of genomic and proteomic alterations occurring within tumors; Tumor pathogenesis, development and progression; Drug-drug interactions; mechanisms of action for novel agents; combination chemotherapy; Pharmacogenomics, pharmacodynamics, and pharmacokinetic properties of anticancer agents; Anticancer chemotherapeutic agents, biological agents, immunomodulatory drugs, cell therapy and gene therapy. The journal publishes original research, reviews, meeting reports, bedside-to-bench reports, letters to the editor, and perspective articles. Cancer Biology & Therapy operates a single-anonymized peer review policy. *Please note that Cancer Biology & Therapy converted to a full Open Access journal from Volume 23 (2022).
From the journal's Aims & Scope
Research area (LetPub): Oncology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer-related Molecular PathwaysMedicine8.3%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology6.2%
- Cell death mechanisms and regulationBiochemistry, Genetics and Molecular Biology5.5%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology5.5%
- Cancer Cells and MetastasisMedicine4.7%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology4.5%
- Cancer Research and TreatmentsBiochemistry, Genetics and Molecular Biology4.5%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q1 · best quartile · 2025
- CiteScore Q1 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceEmbasePublisher website
Other: Adis International Ltd. - Reactions Weekly (Online), National Library of Medicine
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.7LetPub ·
- Impact factor (publisher) 2025
- 5.7Publisher website ·
- 5-year impact factor (publisher) 2025
- 4.5Publisher website ·
- CiteScore 2026-06
- 8.4LetPub ·
- CiteScore (publisher) 2025
- 8.4Publisher website ·
- SJR 2026-06
- 1.41LetPub ·
- SJR (publisher) 2025
- 1.41Publisher website ·
- SNIP 2026-06
- 0.99LetPub ·
- SNIP (publisher) 2025
- 0.99Publisher website ·
- h-index
- 101LetPub ·
- h-index
- 154OpenAlex ·
- i10-index
- 3,322OpenAlex ·
- 2-year mean citedness
- 6.87OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 81LetPub ·
- Articles per year (publisher)
- 3Publisher website ·
- Downloads per year (publisher)
- 968,000Publisher website ·
Articles by year OpenAlex count · 5,222 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 59 | 59 | 14 |
| 2025 | 88 | 88 | 393 |
| 2024 | 115 | 115 | 1,393 |
| 2023 | 88 | 88 | 1,276 |
| 2022 | 65 | 65 | 1,465 |
| 2021 | 57 | 57 | 1,032 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
134 daysMedian, submission to acceptance · P25–P75 97 days – 210 days
- Acceptance to online
- median 11 days (94 articles)
- Submission to online
- median 146 days
- Sample
- 94 articles with submission and acceptance dates (175 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2.3 monthsLetPub ·
- Average acceptance (community reports)
- 50%LetPub ·
- Acceptance rate (publisher)
- 8%Publisher website ·
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 52 daysPublisher website ·
- Acceptance to publication
- 10 daysPublisher website ·
- Submission to publication (journal-reported)
- about 11 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | AUD 4,595 / EUR 3,170 / GBP 2,640 / USD 3,300 | Yes | CC BY, CC BY-NC | |
| OpenAlex | EUR 2,710 / GBP 2,335 / USD 2,970 | — | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted6
- bedside-to-bench reportsThe journal publishes original research, reviews, meeting reports, bedside-to-bench reports, letters to the editor, and perspective articles.Length not stated
- letters to the editorThe journal publishes original research, reviews, meeting reports, bedside-to-bench reports, letters to the editor, and perspective articles.Length not stated
- meeting reportsThe journal publishes original research, reviews, meeting reports, bedside-to-bench reports, letters to the editor, and perspective articles.Length not stated
- original researchThe journal publishes original research, reviews, meeting reports, bedside-to-bench reports, letters to the editor, and perspective articles.Length not stated
- perspective articlesThe journal publishes original research, reviews, meeting reports, bedside-to-bench reports, letters to the editor, and perspective articles.Length not stated
- reviewsThe journal publishes original research, reviews, meeting reports, bedside-to-bench reports, letters to the editor, and perspective articles.Length not stated
Policy excerpts from the journal's websiteOpen access, Peer review
- Open access Open access
Cancer Biology & Therapy is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the discoverability and readership of your article Make an impact and reach new readers, not just thos…
Source ↗Publisher website ·- Peer review
single-anonymized peer review Model summary
Cancer Biology & Therapy operates a single-anonymized peer review policy.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Landes Bioscience
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 2002
- ISSN
- 1538-4047
- Electronic ISSN
- 1555-8576
- Latest issue on the website
- Volume 27, Issue 1 (2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Cancer Biology & Therapy
What CAS zone is Cancer Biology & Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Biology & Therapy is in Zone 2 of Medicine, and in Zone 3 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Biology & Therapy?
The latest impact factor listed by LetPub is 5.7; CiteScore 8.4, h-index 154.
How long does peer review take at Cancer Biology & Therapy?
Based on the dates recorded on 94 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 134 days (interquartile range 97–210 days); authors report an average review time of about 2.3 months; the community-reported acceptance is “about 50%”; the journal's website gives an acceptance rate of 8%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Cancer Biology & Therapy in?
The journal's website gives JCR Q1 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 2 of Medicine.
Which databases index Cancer Biology & Therapy?
According to LetPub and DOAJ records, Cancer Biology & Therapy is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Web of Science and Embase; that list has not been checked against each database.
Is Cancer Biology & Therapy open access, and what is the APC?
Cancer Biology & Therapy is a fully open-access journal. APC about USD 3,300.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .